CLX
Clorox
$106.55
▲ 0.9%Updated Today 11:30 AM ET
CLX at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 44/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 20.8% over the last 12 months
Market Cap
$11.76B
P/E
17.02x
Forward P/E (est.)
15.4x
ROE
453.7%
Revenue Growth
-3.7%
EPS Growth
10.6%
Profit Margin
11.2%
FCF Yield
2.8%
Debt / Equity
7.86x
ROIC
—
Interest Coverage
—
Current Ratio
0.84x
Dividend Yield
5.2%
Implied Growth (rev. DCF)
2.4%
Rating Score
44/100
Clorox (CLX) is a large-cap company in the Household Products industry, part of the Consumer Staples sector of the S&P 500, with a market value around $11.76B.
In its latest reported year it generated about $7.10B in revenue and $810.00M in net profit.
Our model rates CLX Neutral (44/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (7 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
42.5% average over the last 3 years
±3.3 pts around 42.3% across 7 years
grew in 4 of the last 6 year-over-year periods
positive in 7 of 7 years
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CLX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CLX trades near $106.55, around its 50-day average ($93.88) and 200-day average ($106.81). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 48 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. CLX's is $3.04 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CLX found buyers near $88.59 (support) and sellers near $100.73 (resistance); its 52-week range is $84.70–$132.03. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
-0.8%
Revenue moved from $6.21B in 2019 to $7.10B in 2025, a 2.3% compound annual growth rate. The most recent year declined 3.7% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
45.2%
Operating Margin
14.6%
Net Margin
11.4%
ROE
453.7%
Clorox keeps about 11.2% of each sales dollar as net profit, with a 45.2% gross margin and 14.6% operating margin. Return on equity is 453.7%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$2.48B
Net Debt
$1.30B
Net Debt / EBITDA
—
Debt / Equity
7.86x
Leverage: debt-to-equity is 7.9x, with a current ratio of 0.8x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $2.48B of total debt against $1.19B of cash.
Operating CF
$981.00M
Free Cash Flow
$761.00M
FCF Margin
10.7%
In the latest year Clorox produced about $981.00M of operating cash flow and $761.00M of free cash flow after capital spending. That is a free-cash-flow yield of about 2.8% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Dividend yield
5.2%
Per share (latest FY)
$4.88
Total paid (latest FY)
$602.00M
History on record
7 years
dividend uses 79% of free cash flow
74% of net income paid out
total dividends increased 6 years in a row
no cuts in the last 7 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
17.02x
P/S
1.66x
P/B
50.38x
EV / EBITDA
—
CLX trades at 17.0x trailing earnings (about 15.4x on estimated forward earnings), 1.7x sales, and 50.4x book value. Reverse-engineering today's price implies the market expects roughly 2.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$69.64
Current price
$106.55
Starting FCF (latest 10-K)
$761.00M
Growth, years 1–5
-3.7%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where CLX sits versus its Consumer Staples sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 48 Consumer Staples companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How CLX stacks up against its Consumer Staples peers — valuation, profitability, and growth versus the sector median.
In the Consumer Staples sector (74 S&P 500 companies), CLX ranks #29 of 74 by our overall rating. It trades at a discount versus the sector on earnings (17x P/E vs. 22x median) with a higher return on equity (453.7% vs. 18.1%) and slower revenue growth (-3.7% vs. 3.4%).
P/E vs sector
17x
median 22x
ROE vs sector
453.7%
median 18.1%
Growth vs sector
-3.7%
median 3.4%
Sector rank
#29
of 74 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Consumer Staples companies by sub-industry and size. Sector median is across all 74 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $106.55 today · expected CAGR -5% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $7.32B | $7.54B | $7.76B | $8.00B | $8.24B |
| Net income | $804.88M | $829.03M | $853.90M | $879.52M | $905.90M |
| EPS | $7.29 | $7.51 | $7.74 | $7.97 | $8.21 |
| Share price (low) | $72.92 | $75.11 | $77.36 | $79.68 | $82.07 |
| Share price (high) | $123.96 | $127.68 | $131.51 | $135.46 | $139.52 |
| CAGR (low–high) | -32% / 16% | -16% / 9% | -10% / 7% | -7% / 6% | -5% / 6% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CLX:
- Strong return on equity (453.7%) shows capital is put to work well.
- Pays a 5.2% dividend on top of any price gains.
The case against CLX:
- Revenue growth is slow/negative (-3.7%), limiting the upside engine.
- Elevated leverage (debt/equity 7.9x) adds financial risk.
Balance-sheet risk — debt/equity of 7.9x magnifies the impact of higher rates or weaker earnings.
Growth risk — sluggish revenue (-3.7%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Clorox is a large-cap consumer staples business with shrinking revenue, with modest profitability, and a heavier debt load to watch. It trades at 17.0x earnings, which our model scores Neutral (44/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 27 Wall Street analysts covering CLX recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-4 pts of buy ratings).
Latest SEC Filings
CLX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
CLX — frequently asked questions
Is CLX a good stock to buy?
We don't give buy or sell advice. Our model rates Clorox Neutral (44/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is CLX's rating on The Stocks School?
Clorox currently scores 44/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does CLX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Clorox's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for CLX calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this CLX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell CLX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.